Commerzbank set a €98.00 ($120.99) price objective on MorphoSys (ETR:MOR) in a research report report published on Monday. The brokerage currently has a buy rating on the stock.

MOR has been the topic of a number of other reports. Oddo Bhf set a €90.00 ($111.11) price objective on MorphoSys and gave the company a buy rating in a report on Tuesday, February 20th. JPMorgan Chase & Co. set a €97.00 ($119.75) price objective on MorphoSys and gave the company a buy rating in a report on Friday, December 29th. Berenberg Bank set a €85.00 ($104.94) price objective on MorphoSys and gave the company a buy rating in a report on Thursday, December 7th. HSBC set a €64.00 ($79.01) price objective on MorphoSys and gave the company a sell rating in a report on Friday, January 19th. Finally, Independent Research set a €93.00 ($114.81) price objective on MorphoSys and gave the company a buy rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of €84.02 ($103.73).

How to Become a New Pot Stock Millionaire

Shares of MorphoSys stock opened at €84.95 ($104.88) on Monday. MorphoSys has a 1 year low of €49.63 ($61.27) and a 1 year high of €88.10 ($108.77). The firm has a market capitalization of $2,490.00 and a PE ratio of -35.25.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/morphosys-mor-given-a-98-00-price-target-by-commerzbank-analysts/1958557.html.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.